Skip to main content
Sign In
 

Liver Disease

Liver Disease Related Trials


For more information regarding these clinical trials,
please call 303-315-1135.

Name Principal Investigator

Utility of transarterial chemoembolization for hepatocellular carcinoma in the liver transplant candidate: an intention- to- transplant analysis

Gregory T. Everson, MD

Accuracy of pre-transplantation diagnosis of hepatocellular carcinoma based on imaging and clinical presentation: comparison with explant histology

Gregory T. Everson, MD

Increased immunosuppressant levels in hepatitis C liver transplant recipients

James F. Trotter, MD

Treatment of hepatitis C virus (HCV) following liver transplantation

James F. Trotter, MD

Adult to adult living donor liver transplantation (A2ALL) cohort study: retrospective study protocol (A2ALL RETRO-01)

James F. Trotter, MD

Transjugular intrahepatic portosystemic shunt (TIPS) versus liver transplantation in the treatment of Budd-Chiari syndrome: experience at our institution and a review of the literature

Augustin R. Attwell, MD

Significant disparity in MELD (Model for Endstage Liver Disease) scores of liver transplantation recipients based on size of waiting list: impact of organ allocation and patient outcomes

James F. Trotter, MD

Characteristics of liver transplantation centers performing adult to adult living donor transplantation

James F. Trotter, MD

Gallbladder stent placement for the treatment of symptomatic gallstone disease in patients with cirrhosis

James F. Trotter, MD

A patient survey of metabolic complications after liver transplantation: determination of perceptions regarding complications and their management practice patterns

Lisa M. Forman, MD

Metabolic complications after liver transplantation: characterization and determination of physician attitudes and practice patterns

Lisa M. Forman, MD

Pre-study serial histology as a predictor of response to continuous therapy during the HALT-C trial

Gregory T. Everson, MD

Quantitative assessment of hepatic function in chronic HCV

Gregory T. Everson, MD

A randomized, double blind trial of telbivudine (LDT) versus Lamivudine in adults with decompensated chronic hepatitis B and evidence of cirrhosis

Gregory T. Everson, MD

A double blind, randomized, placebo-controlled, multi-centre, dose ranging, parallel group, Phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, 75 MG once daily for  12 weeks in subjects with chronic hepatitis C-related thrombocytopenia who are potential candidates for antiviral  treatment with pegylated interferon and ribavirin

Gregory T. Everson, MD

The A2ALL LADR protocol: pre-transplant treatment to prevent recurrence of hepatitis C after living donor liver transplantation

Gregory T. Everson, MD

Liver recipients in the HCUP database: a study of hospital utilization and costs

Lisa M. Forman, MD

A prospective, randomized, multicenter, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon Alfa-2A (Pegasys) plus ribavirin vs. no prophylaxis following liver transplantation for hepatitis C.

Gregory T. Everson, MD

The pharmacokinetics of myfortic (mycophenolic acid) in liver transplant recipients

James F. Trotter, MD

The hepatitis C antiviral long-term treatment to prevent cirrhosis (Halt-C) trial: a randomized controlled trial to evaluate the safety and efficacy of long-term peginterferon Alfa-2A for treatment of chronic hepatitis C in patients who failed to respond to previous interferon therapy

Gregory T. Everson, MD

Adult to adult living donor liver transplant cohort study

James F. Trotter, MD

A Phase I double blind, placebo controlled, dose escalation, multicenter therapeutic trial of the safety, immunogenicity, and efficacy of GI-5005; an inactivated recombinant saccharomyces cerevisiae expressing a hepatitis C virus NS3-core fusion protein, in patients with chronic hepatitis C infection

Gregory T. Everson, MD

Immune responses in acute hepatitis C infection

Hugo R. Rosen, MD

A Phase II trial to assess the safety of immunosuppression withdrawal in liver transplant recipients with hepatitis C

James F. Trotter, MD

A prospective, open-label, multi center, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regime with mycophenolate mofetil and sirolimus in recipients of an orthotopic liver transplant

James F. Trotter, MD

Hepatic research registry

James F. Trotter, MD

A double blind, placebo controlled, randomized Phase III study of intravenous terlipressin in patients with hepatorenal syndrome type I.

Gregory T. Everson, MD

A pilot study for the use of the secure continuous remote alcohol monitor (SCRAM) in patients listed for liver transplantation

James F. Trotter, MD

HCV RNA testing in Halt-C sustained virologic responders

Gregory T. Everson, MD

PVCLD national registry database for pulmonary vascular complications of liver disease

James F. Trotter, MD

Restoration of hepatic function in living liver donors (an ancillary study of A2ALL)

Gregory T. Everson, MD

A phase II multicenter trial to assess the safety and efficacy of campth-1H and tacrolimus followed by immunosuppression withdrawal in liver transplantation

James F. Trotter, MD

Hepatitis C immunity in the human liver transplant model

Hugo R. Rosen, MD

Randomized evaluation of fibrosis due to hepatitis C after de novo liver transplant (refine) a multicenter, randomized, open-label study to compare the development of liver fibrosis at 12 months after transplantation for hepatitis C cirrhosis in patients receiving either neural or tracrolimus

James F. Trotter, MD

Protocol for the collection of specimens used in Abbott laboratories in vitro diagnostic hepatitis assay clinical studies (7B5-02-04Z01-01)

James F. Trotter, MD

A randomized, controlled, multicenter study of thymoglobulin induction therapy with a calcineurin-inhibitor sparing regimen in liver transplant patients

James F. Trotter, MD

Changes of metabolic profiles in urine from long-term liver transplant patients as a potential marker for immunosuppressant nephrotoxicity

James F. Trotter, MD

Changes of metabolic profiles in urine from de novo liver transplant patients during the first 12 months after transplantation as a potential marker of immunosuppressant nephrotoxicity